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Introduction. Patients with a positive sentinel lymph node biopsy may undergo delayed completion axillary dissection. Where
intraoperative analysis is available, immediate completion axillary dissection can be performed. Alternatively, patients may
undergo primary axillary dissection for breast cancer, historically or when preoperative assessment suggests axillary metastases.
This study aims to determine if there is a diﬀerence in the total number of lymph nodes or the number of metastatic nodes
harvested between the 3 possible approaches. Methods. Three consecutive comparable groups of 50 consecutive patients who
underwent axillary dissection in each of the above contexts were identified from the Portsmouth Breast Unit Database. Patient
demographics, clinicopathological variables, and surgical treatment were recorded. The total pathological nodal count and the
number of metastatic nodes were compared between the groups. Results. There were no diﬀerences in clinico-pathological features
between the three groups for all features studied with the exception of breast surgical procedure (P < 0.001). There were no
diﬀerences in total nodal harvest (P = 0.822) or in the number of positive nodes harvested (P = 0.157) between the three groups.
Conclusion. The three approaches to axillary clearance yield equivalent nodal harvests, suggesting oncological equivalence and
robustness of surgical technique.
1. Introduction
The role of axillary surgery in breast cancer is to stage
the axilla and in those with lymph node metastases to
treat the axilla with axillary clearance [1]. Adequate axillary
dissection is important in node-positive patients both to
ensure removal of all involved nodes to optimise local control
and to obtain the maximum prognostic information [2].
When staging the axilla, an additional goal, particularly in
node-negative patients, is to minimise morbidity. Various
strategies for doing so have been developed, the most recent
being dual localisation sentinel lymph node biopsy (SLNB).
This has been recommended by the United Kingdom
National Institute for Health and Clinical Excellence as the
“preferred technique” for staging the axilla in radiologically
or cytologically (where tested) node-negative patients [3].
If SLNB analysis demonstrates metastasis to the axilla, it is
recommended that patients undergo axillary clearance [4].
Traditionally, sentinel lymph nodes are analysed histo-
logically, and patients who are found to have metastases
in these nodes often undergo a delayed completion axillary
dissection (dALND) after a delay when the histological
result is available. In two large United Kingdom datasets of
SLNB, the ALMANAC trial [5] and the New Start training
programme [6], approximately 30% of patients were SLNB
positive and therefore required further axillary surgery.
Alternative analysis techniques have been developed for use
in conjunction with SLNB to enable rapid intraoperative
analysis of sentinel lymph nodes including touch imprint
cytology, frozen section analysis, and molecular analysis such
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as OSNA and the Veridex polymerase chain reaction (PCR)
assay as used in our institution. These diagnostic techniques
enable node-positive patients to undergo immediate axillary
clearance under the same general anaesthetic (GA) without
the need for a second operation and another GA.
Anecdotally, dALND is often more technically challeng-
ing than primary axillary clearance or immediate completion
axillary dissection (iALND) following intraoperative SLNB
analysis. This is supported by data from Goyal et al., who
have shown that a dALND requires a greater operative
time than iALND [7]. With increased diﬃculty associated
with delayed axillary clearance, it is important to establish
whether optimal oncological results are maintained using
this approach. It is also important to establish oncological
equivalence between primary axillary clearance and SLNB
with iALND, as although there is no scarring to contendwith,
the axillary contents are fragmented by the latter approach.
Chakravorty et al. have shown no diﬀerence in median nodal
yields from axillary clearance with or without SLNB, in either
the immediate or delayed setting [8]. Earlier studies support
these findings, but only compared two of the three possible
patient groups [7, 9].
We determined to assess the nodal harvest from the axilla
in these various contexts, within a single centre, with the
same surgeons and pathologists all working in accordance
with the same standardised protocols. Our hypothesis was
that dALND might yield a lower number of lymph nodes
due to increased technical diﬃculty and scarring compared
to iALND.
2. Methods
2.1. Techniques. Sentinel node biopsy using dual localisation
with radioisotope and Patent Blue V dye was introduced
into Portsmouth Breast Unit for staging the axilla in breast
cancer in 1999 as part of the ALMANAC trial. After the initial
trial results in 2004, SLNB was adopted as the standard of
care for all patients with clinical or radiological T1 cancers.
Axillary clearance without sentinel node biopsy remained the
standard approach for those with more advanced tumours.
During 2006, the application of SLNB was extended to
tumours up to 3 cm in diameter. From December 2007,
after the introduction of intra-operative assessment using
a PCR-based assay, SLNB became the index standard for
axillary assessment of all breast cancer patients irrespective
of T-stage, unless there was clinical or radiological evidence
of nodal involvement. All operations were performed or
supervised by consultant surgeons, unless a dedicated breast
surgical trainee had completed accreditation with the SLNB
technique. Sentinel nodes were sectioned into 2mm slices
and alternate sections analysed by PCR and conventional
histology.
2.2. Patient Cohorts. Portsmouth Breast Unit maintains a
prospective database of all patients undergoing surgical treat-
ment of breast cancer. From this, 50 consecutive histologi-
cally node-positive patients were retrospectively identified in
each of the three groups. The sample size was determined by
the size of our smallest group (those undergoing iALND),
with the other patient groups matched in number. Group
1 consisted of consecutive node-positive patients who had
undergone primary axillary clearance prior to November
2007; group 2 consisted of patients who had undergone
SLNB and proceeded to dALND following histological node
analysis following the introduction of SLNB but prior to
the adoption of intra-operative analysis (between November
2007 and November 2009); group 3 consisted of consecutive
patients who had undergone SLNB and iALND following
positive intra-operative SLNB PCR analysis (after November
2009).
2.3. Data Collection. Data was collected from electronic
histopathological and clinic letter databases and analysed
using SPSS v14 (SPSS Inc., IBM). Data collected included
age, sex, tumour type, grade, size (T score), hormone recep-
tor status (oestrogen and progesterone), HER-2 receptor
status, and the nature of surgery performed on the breast
primary. Histological invasive tumour size was documented
in all cases, and total tumour size was noted in the histology
report. T score was determined on the basis of invasive
tumour size or multifocality. Statistical analysis was per-
formed to test the null hypothesis that all patients were taken
from the same population group. Age was analysed using
analysis of variance (ANOVA), and all other parameters were
assessed using Pearson’s Chi-Squared test.
Outcome measures were determined. The primary out-
come was the total number of lymph nodes harvested from
the axilla (combining axillary dissection with sentinel node
harvest where performed). The secondary outcome was
the total number of histologically positive lymph nodes
harvested. Where not explicitly stated, nodal metastases
were assumed to be macrometastases without extracapsular
spread. Where lymph nodes were PCR positive but histologi-
cally negative, histological specimens were sent for immuno-
histochemistry. Statistical significance testing against the null
hypothesis was performed using ANOVA.
3. Results
Our three groups were statistically similar in all respects,
except the nature of surgery performed on the primary breast
tumour (see Table 1). Our patient groups were similar in
terms of sex, with only one male among 150 patients. The
mean ages ranged from 59.6 to 63.4 years. Tumour size, as
reflected by T score, was similar across patient groups, with
the majority of tumours less than 5 cm in diameter (T1 and
T2). There were similar numbers of multifocal tumours in
the three groups (range 7 to 11). Tumour grades were similar,
with the majority of tumours being graded 2 or 3, and most
tumours were of ductal type. Oestrogen and progesterone
receptors positivity dominated, and few tumours tested
positive for HER-2 receptors. Patients in group 1 were
more likely to have their primary tumours treated with
mastectomy than breast conserving treatment, in contrast
with groups 2 and 3. This diﬀerence was most marked in
group 2, where only 2 patients underwentmastectomy. These
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Table 1: Clinicopathological Features. Clinico-pathological features for the three cohorts examined. Age was analysed using Analysis of
Variance (ANOVA), other parameters using Pearson’s Chi-Squared test. Group classification of patients by axillary procedure: group 1:
primary axillary clearance; group 2: SLNB and dALND; group 3: SLNB and iALND.
Group 1 Group 2 Group 3 Significance (P)
Sex F :M 50 : 0 49 : 1 50 : 0 0.365
Age
Mean 63.4 59.6 59.6
0.191a95% CI 59.2–67.5 56.6–62.6 56.8–62.4
T size
1 16 28 13
0.096
2 21 15 21
3 3 0 4
4 1 0 1
MF 9 7 11
Grade
1 3 5 5
0.7282 27 29 32
3 19 16 12
Other 1 0 1
Type
Ductal 41 40 39
0.957Lobular 3 4 3
Other 6 6 8
ER
−ve 14 7 10
0.222+ve 36 43 40
PR
−ve 16 9 12
0.265+ve 34 41 38
HER-2
−ve 37 40 35
0.521+ve 3 5 4
Indeterminate 10 5 11
Surgery
Local excision 16 48 29
<0.001Mastectomy 30 2 13
Oncoplastic 4 0 8
a
Analysis of Variance.
Table 2: Outcome Measures. Group classification of patients by axillary procedure: group 1: primary axillary clearance; group 2: SLNB and
dALND; group 3: SLNB and iALND.
Group 1 Group 2 Group 3 Significance (P)
Total nodes Median 14 14 14 0.822
Positive nodes Median 2 2 2 0.157
diﬀerences in nature of surgery performed on the breast were
strongly statistically significant (P < 0.001).
All three patient groups were statistically similar regard-
ing both outcome measures—total number of nodes har-
vested from the axilla and the total number of positive nodes
harvested (Table 2 and Figures 1 and 2). The mean total
number of nodes harvested ranged from 14.6 to 15.4 with
clearly overlapping 95% confidence intervals as illustrated
in Figure 1. The mean number of positive nodes was higher
in group 1 at 5.1, compared with 3.2 and 3.52 in groups 2
and 3, respectively, but 95% confidence intervals overlap, and
no statistically significant diﬀerence was found (Figure 2).
Consistent with this the median total number of nodes
harvested was 14 in all three groups. The median number
of positive nodes was also 2 across all patient groups.
4. Discussion
Here, we demonstrate that both the total number of lymph
nodes harvested from the axilla and the number of positive
nodes are unaﬀected, whether axillary clearance is performed
as a primary procedure, as a delayed procedure following
SLNB, or as an immediate procedure following intra-
operative analysis of sentinel lymph nodes (SLN). This
confirms recent findings [8].
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Figure 1: Mean total number of nodes harvested in the three
cohorts (±95% confidence interval). Group classification of
patients by axillary procedure: group 1: rimary axillary clearance;
group 2: SLNB and dALND; group 3: SLNB and iALND.
The mean number of positive nodes harvested was
higher, although not significantly so, in patients undergoing
primary axillary clearance compared to those having an
axillary clearance following SLNB. This tendency may reflect
bias due to preoperative selection of patients with clinically
or radiologically positive nodes in the primary axillary clear-
ance cohort.
Our patient groups were comparable over all parameters
except the nature of surgery performed on the primary breast
tumour. This demonstrates that our results are valid, as
although our patients were selected by being consecutive
rather than through a rigorous case matching process, the
groups were statistically similar in all but one measured
characteristic. The diﬀerence between groups in the nature
of surgery performed is likely to be the result of previous
local policy, prior to the introduction of intra-operative
SLN analysis, if only oﬀering SLNB to patients with smaller
breast tumours undergoing breast conserving surgery. With
the introduction of intra-operative SLN analysis, SLNB was
oﬀered to all clinically and radiologically node-negative
patients.
It is documented that nodal harvest is determined not
only by surgical technique, but also by the degree to which
nodes are pursued at histopathological analysis [10]. In
this single-centre study, we believe that variations in lymph
node count due to individual surgeon or pathologist-specific
technique is likely to have been minimised by standardised
surgical and pathological protocols.
5. Conclusion
We conclude from this study that there is no statistically
significant diﬀerence in the number of lymph nodes or num-
ber of positive nodes harvested from the axilla, regardless of
timing of axillary clearance or the use of SLNB. The goal of
axillary clearance is to remove all potentially involved lymph
nodes and fatty tissue, and using the number of nodes as
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Figure 2: Mean number of positive nodes harvested in the three
cohorts (±95% confidence interval). Group classification of pa-
tients by axillary procedure: group 1: primary axillary clearance;
group 2: SLNB and dALND; group 3: SLNB and iALND.
a measure of adequacy of tissue retrieval, we have shown
equivalence between each technique in our unit. Therefore,
even in more surgically challenging circumstances, such as
the scarred axilla of a previous SLNB, surgical technique is
robust in ensuring adequate clearance of the axilla.
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